Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer

<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Accurate evaluation of axillary lymph node (ALN) involvement is mandatory before treatment of primary breast cancer. The aim of this study is to compare preoperative diagnostic accuracy between positron emission tomography/computed tomography with <jats:sup>18</jats:sup>F-fluorodeoxyglucose (<jats:sup>18</jats:sup>F-FDG PET/CT) and axillary ultrasonography (AUS) for detecting ALN metastasis in patients having operable breast cancer, and to assess the clinical management of axillary <jats:sup>18</jats:sup>F-FDG PET/CT for therapeutic indication of sentinel node biopsy (SNB) and preoperative systemic chemotherapy (PSC).</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>One hundred eighty-three patients with primary operable breast cancer were recruited. All patients underwent <jats:sup>18</jats:sup>F-FDG PET/CT and AUS followed by SNB and/or ALN dissection (ALND). Using <jats:sup>18</jats:sup>F-FDG PET/CT, we studied both a visual assessment of <jats:sup>18</jats:sup>F-FDG uptake and standardized uptake value (SUV) for axillary staging.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>In a visual assessment of <jats:sup>18</jats:sup>F-FDG PET/CT, the diagnostic accuracy of ALN metastasis was 83% with 58% in sensitivity and 95% in specificity, and when cut-off point of SUV was set at 1.8, sensitivity, specificity, and accuracy were 36, 100, and 79%, respectively. On the other hand, the diagnostic accuracy of AUS was 85% with 54% in sensitivity and 99% in specificity. By the combination of <jats:sup>18</jats:sup>F-FDG PET/CT and AUS to the axilla, the sensitivity, specificity, and accuracy were 64, 94, and 85%, respectively. If either <jats:sup>18</jats:sup>F-FDG PET uptake or AUS was positive in allixa, the probability of axillary metastasis was high; 50% (6 of 12) in <jats:sup>18</jats:sup>F-FDG PET uptake only, 80% (4 of 5) in AUS positive only, and 100% (28 of 28) in dual positive. By the combination of AUS and <jats:sup>18</jats:sup>F-FDG PET/CT, candidates of SNB were more appropriately selected. The axillary <jats:sup>18</jats:sup>F-FDG uptake was correlated with the maximum size and nuclear grade of metastatic foci (p = 0.006 and p = 0.03).</jats:p> </jats:sec> <jats:sec> <jats:title>Conclusion</jats:title> <jats:p>The diagnostic accuracy of <jats:sup>18</jats:sup>F-FDG PET/CT was shown to be nearly equal to ultrasound, and considering their limited sensitivities, the high radiation exposure by <jats:sup>18</jats:sup>F-FDG PET/CT and also costs of the examination, it is likely that AUS will be more cost-effective in detecting massive axillary tumor burden. However, when we cannot judge the axillary staging using AUS alone, metabolic approach of <jats:sup>18</jats:sup>F-FDG PET/CT for axillary staging would enable us a much more confident diagnosis.</jats:p> </jats:sec>